Is MANE or MAZE more undervalued in 2026?

CirclFi compares Veradermics, Incorporated (MANE) and Maze Therapeutics, Inc. (MAZE) using 13 institutional-grade valuation models. MANE has a Quality of Company score of 5.0/10 while MAZE scores 5.4/10.

Which is a better buy — MANE or MAZE?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do MANE and MAZE valuations compare?

MANE at $102.88 and MAZE at $26.40 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

MANE vs MAZE Valuation Comparison 2026 — Intrinsic Value Analysis

MANE

Biotechnology

Veradermics, Incorporated

Quality

5.0

out of 10

Value Trap

—

Price

$102.88

Last close

Models

10/13

Active

MAZE

Biotechnology

Maze Therapeutics, Inc.

Quality

5.4

out of 10

Value Trap

—

Price

$26.40

Last close

Models

9/13

Active

Model-by-Model Comparison

Model	Type	MANE Fair Value	MANE Upside	MAZE Fair Value	MAZE Upside
Bayesian DCF	Intrinsic	$32.70	-68.2%	$3.40	-87.1%
Earnings Power Value	Intrinsic	$29.35	-56.7%	—	—
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$7.73	-92.5%	$7.76	-71.4%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for MANE vs MAZE — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

MANE vs MAZE — Which Stock Is More Undervalued?

MAZE scores higher with a 5.4/10 quality rating vs MANE's 5.0/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Veradermics, Incorporated (MANE) and Maze Therapeutics, Inc. (MAZE) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

MANE currently trades at $102.88 with a QOC of 5.0/10, while MAZE trades at $26.40 with a QOC of 5.4/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).